SRSF2 and RUNX1 mutations were associated with reduced survival in MDS30; however, the SF3B1 mutation was a predictor of favorable prognosis in MDS and MDS/MPN.31, 32. Here, SF3B1 is linked to myeloproliferative neoplasm.